Reports
Sale
Global Generic Drugs Market Size, Trends, Report, Forecast: By Brand: Pure Generic, Branded Generic; By Indications: Central Nervous System (CNS), Cardiovascular, Dermatology, Oncology, Respiratory, Others; By Route of Administration: Oral, Others; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2023-2031
Global Generic Drugs Market Outlook
The global generic drugs market reached a value of almost USD 411.8 billion in 2022, driven by the significant rise in the cardiometabolic risk factors among the population. The market size is anticipated to grow at a CAGR of 5.5% during the forecast period of 2023-2031 to achieve a value of USD 666.8 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global generic drugs market is driven by the rising cardiometabolic risk factors across the globe. The United States is the leading regional market. This can be attributed to the implementation of rigorous reviews by the numerous regulatory bodies to ensure optimum standards during the manufacturing of these drugs, further aiding the market growth in the region.
Market Segmentation
Generic drugs are referred to as the bioequivalent of brand-name drugs on the basis of safety, strength, quality, stability, impact, intended use, dosage form, and the route of administration. These drugs are established to be safe and effective just as their already marketed brand-name formulation. Generic drug manufacturers are not required to invest in drug research or drug development and marketing, which makes these medicines cost-effective, thereby contributing to their widespread preference.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The generic drugs market is segmented on the basis of application into:
- CNS
- Cardiovascular
- Dermatology
- Genitourinary/Hormonal
- Respiratory
- Rheumatology
- Diabetes
- Oncology
- Others
Among all of these, cardiovascular diseases represent the largest segment in the market.
On the basis of drug delivery, the industry is divided into:
- Oral
- Injectables
- Dermal/Topical
- Inhalers
Oral generic drugs at present account for a majority of the total market share.
On the basis of distribution channel, the industry is bifurcated into:
- Retail Pharmacies
- Hospital Pharmacies
Out of these, retail pharmacies represent a clear dominance in the global generic drugs market.
The report also covers the regional markets like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The global generic drugs market is driven by the significant rise in the cardiometabolic risk factors among the population. In addition to this, due to various factors, such as changing dietary patterns, sedentary lifestyles, and hectic working schedules, there is a growing prevalence of diabetes, dyslipidaemia, hypertension, metabolic syndrome, and obesity. This has resulted in a considerable rise in the uptake of medicines, thereby accelerating the growth of the industry.
The global generic drugs market is further enhanced by the huge costs related to the medication of various chronic and lifestyle diseases, which have led to the increase in the consumer inclination toward affordable variants, further boosting the demand. Apart from this, the patent expiration of crucial blockbuster drugs, in conjunction with multiple favourable initiatives undertaken by the governments of several countries to promote the usage of generic drugs, is anticipated to propel the industry growth. Numerous regulatory bodies are implementing rigorous reviews to ensure optimum standards during the manufacturing of these drugs.
Competitive Landscape
The report gives a detailed analysis of the following key players in the global generic drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Fresenius Kabi AG
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Brand |
|
| Breakup by Indications |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Generic Drug Market Overview
3.1 Global Generic Drug Market Historical Value (2016-2022)
3.2 Global Generic Drug Market Forecast Value (2023-2031)
4 Global Generic Drug Market Landscape
4.1 Global Generic Drug Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Generic Drug Product Landscape
4.2.1 Analysis by Brand
4.2.2 Analysis by Indications
4.2.3 Analysis by Route of Administration
5 Global Generic Drug Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Generic Drug Market Segmentation
6.1 Global Generic Drug Market by Brand
6.1.1 Market Overview
6.1.2 Pure Generic
6.1.3 Branded Generic
6.2 Global Generic Drug Market by Indications
6.2.1 Market Overview
6.2.2 Central Nervous System (CNS)
6.2.3 Cardiovascular
6.2.4 Dermatology
6.2.5 Oncology
6.2.6 Respiratory
6.2.7 Others
6.3 Global Generic Drug Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Topical
6.3.4 Parenteral
6.3.5 Others
6.4 Global Generic Drug Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Homecare
6.4.4 Specialty Centers
6.4.5 Others
6.5 Global Generic Drug Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital Pharmacy
6.5.3 Online Pharmacy
6.5.4 Retail Pharmacy
6.6 Global Generic Drug Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Generic Drug Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Generic Drug Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Generic Drug Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Generic Drug Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Generic Drug Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 Teva Pharmaceuticals Industries Ltd.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Mylan NV
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Novartis AG
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Pfizer Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Sun Pharmaceutical Industries Ltd.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Fresenius SE & Co. KGaA
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Lupin
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Endo International plc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Aurobindo Pharma
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Novartis AG
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Hikma Pharmaceuticals PLC.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 STADA Arzneimittel AG
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Eli Lilly and Company
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Aspen Holdings
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
19 Global Generic Drug Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global market for generic drugs reached a total of USD 411.8 billion in 2022.
The market is anticipated to grow at a CAGR of 5.5% during the forecast period of 2023-2031 to reach a value of USD 666.8 billion by 2031.
The major drivers of the industry include rising disposable incomes, increasing population, rising cardiometabolic risk factors, and the implementation of rigorous reviews by the numerous regulatory bodies to ensure optimum standards during the production of these drugs.
Various favourable initiatives undertaken by the governments of multiple countries is expected to be a key trend guiding the growth of the industry.
North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market.
Cardiovascular disease is the dominant application segment in the industry.
Oral generic drugs are the leading delivery type of the product in the industry.
The retail pharmacies account for the largest market share, among other distribution channels in the industry.
The leading players in the industry are Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis AG, Sun Pharmaceutical Industries Ltd., and Fresenius Kabi AG, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999$5999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER